• Schizophrenia:
    • 10-15mg OD
    • Increase dose every 2 weeks
    • Max: 30mg/day
    • Doses >15mg/day rarely more effective
  • Acute and maintenance treatment of manic or mixed episodes associated with bipolar I disorder:
    • Monotherapy: 15mg OD
      • Max: 30mg/day
    • Valproate/lithium adjunct: 10-15mg OD
      • Max: 30mg/day
  • Major depressive order:
    • 2-5mg OD
    • Increased up to 5mg/day every week
    • Max: 15mg/day

Tablet:

  • 10mg
  • 15mg
  • 30mg
  • Discontinue if unexplained decrease in WBCs
  • May be taken with/without food

Atypical antipsychotic

The exact mechanism of action unknown but is thought to partially agonize dopamine D2 and serotonin 5-HT1A receptors and antagonize serotonin 5-HT2A receptors.

  • Headache
  • Weight gain
  • Anxiety
  • Insomnia
  • Nausea
  • Vomiting
  • Lightheadedness
  • Dizziness
  • Somnolence
  • Sedation
  • Akathisia
  • Injection site reaction (IM use)
  • Constipation
  • Incontinence
  • Blurred vision
  • Extrapyramidal symptoms
  • Tremor
  • Xerostomia
  • Cough
  • Restlessness
  • Fatigue
  • Arthralgia
  • Myalgia
  • Sialorrhea
  • Diarrhea (peds patients)
  • Fever (peds patients)
  • Appetite increased
  • Dyslipidemia
  • Hyperglycemia
  • Impaired body temperature regulation
  • Compulsive behaviors
  • Hypersensitivity to class/ components
  • Dementia-related psychosis
  • Suicidal thoughts and behaviours
  • Cisapride
  • Thioridazine

                          Drug Status

Availability Prescription only
Pregnancy Use with caution
Breastfeeding Use with caution
Schedule Controlled
BRAND NAME STRENGTH FORMULATION PACK SIZE MANUFACTURER DISTRIBUTOR
Aripitas 10mg Tablet 30’s Intas Pharma Accord Healthcare
Aripitas 15mg Tablet 30’s Intas Pharma Accord Healthcare
Aripitas 30mg Tablet 30’s Intas Pharma Accord Healthcare